Working collaboratively for impact Sample Clauses

Working collaboratively for impact. We will continue to work collaboratively with other HEIs and our target schools and colleges in order to ensure an effective outreach programme. As part of HEFCE’s National Networks for Collaborative Outreach initiative, the universities of Portsmouth, Southampton, Winchester, Southampton Solent, Bournemouth and the Arts University Bournemouth have set up the Southern Universities Network (SUN). This partnership built upon and extended our previous collaboration under the Hampshire Universities WP Group. Across the SUN we have committed to provide outreach opportunities for all state schools and colleges in our region of Dorset, Hampshire and the Isle of Wight. We will also exchange good practice and share effective approaches to WP. Our particular focus for collaborative working in 2016/17 covers: Focus Activities Continuing Professional Development (staff and student union) SUN will arrange staff development for WP practitioners including student ambassadors and Students’ Union officers. Vulnerable children & young people SUN will continue in partnership to develop and promote wider understanding of the issues facing vulnerable children and young people. We will work in partnerships with local authorities and voluntary sector agencies. This work will be informed by the National Network for the Education of Care Leavers. BME work SUN will continue to promote and support the progression of students from minority ethnic communities, working with community groups and sharing our networks to maximise opportunities for collaborative delivery. Disability SUN will develop and extend collaborative projects which support the progression of students with disabilities, drawing on the expertise of specialists within our universities, current students with disabilities and those working in the field. We will continue to work collaboratively with other institutions across the South East as part of the Higher Education Access and Tracking (HEAT) service. This provides a collaborative targeting, monitoring and evaluation service in support of our outreach work. It allows us to report on the impact of our activities in terms of progression to any HEI. It also provides systems and data to underpin an evidence base for WP practice and reporting. Recent reports show us that progression to HE from our outreach activity with quintiles 1&2 (POLAR 3) is 34% as opposed to the national average for these groups of less than 25%. In 2016/17 we will maintain our membership of the Sou...
AutoNDA by SimpleDocs
Working collaboratively for impact. We will continue to work collaboratively with other Universities in our AimHigher partnership to obtain maximum impact from our combined activities, through co‐operation and appropriate targeting of schools and colleges and shared resources. Collaborative activity will include joint ambassador training, partnership work with care leavers and sharing of appropriate data to enable close targeting and monitoring of outcomes. Our current AimHigher partners are the Universities of Southampton, Southampton Solent and Winchester. We also work with the Smallpeice Trust and deliver four STEM focused 4 day residential courses each year for year 19 and 10 pupils. In 2010 this included an Engineering Experience course particularly targeted at WP applicants and females.

Related to Working collaboratively for impact

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Additional Information for Product Development Projects Outcome of product development efforts, such copyrights and license agreements. • Units sold or projected to be sold in California and outside of California. • Total annual sales or projected annual sales (in dollars) of products developed under the Agreement. • Investment dollars/follow-on private funding as a result of Energy Commission funding. • Patent numbers and applications, along with dates and brief descriptions.  Additional Information for Product Demonstrations: • Outcome of demonstrations and status of technology. • Number of similar installations. • Jobs created/retained as a result of the Agreement.

  • Joint Inventions For Subject Inventions conceived or first actually reduced to practice under this Agreement that are joint Subject Inventions made by CONTRACTOR and USER, each Party shall have the option to elect and retain title to its undivided rights in such joint Subject Inventions.

  • For clarity the time allowances provided in clause 2.10 shall operate to reduce the maximum timetabled classroom teaching time specified in clause 4.2 of this agreement.

  • AREAS OF COLLABORATION The School will collaborate under Xxxx Innovation Mission to establish, operate and support ATL in India within the school premises with financial support from NITI Aayog.

  • Team Teaching Unit members participating in team teaching assignments will receive formula hour credit in proportion to the percentage of in-class involvement. When team-taught class sizes exceed the normal, the formula conditions specified in Section 4.3.3 shall apply.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Time is Money Join Law Insider Premium to draft better contracts faster.